These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 7222314

  • 1. Urine composition in patients with urolithiasis during treatment with magnesium oxide.
    Tiselius HG, Ahlstrand C, Larsson L.
    Urol Res; 1980; 8(4):197-206. PubMed ID: 7222314
    [Abstract] [Full Text] [Related]

  • 2. A biochemical basis for grouping of patients with urolithiasis.
    Tiselius HG, Almgård LE, Larsson L, Sörbo B.
    Eur Urol; 1978; 4(4):241-9. PubMed ID: 668734
    [Abstract] [Full Text] [Related]

  • 3. Urine composition in patients with renal stone disease during treatment with allopurinol.
    Tiselius HG, Larsson L.
    Scand J Urol Nephrol; 1980; 14(1):65-71. PubMed ID: 7375845
    [Abstract] [Full Text] [Related]

  • 4. Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis.
    Takasaki E.
    Invest Urol; 1975 Jan; 12(4):251-4. PubMed ID: 1112654
    [Abstract] [Full Text] [Related]

  • 5. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
    Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, Hou K.
    Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
    [Abstract] [Full Text] [Related]

  • 6. [Clinical studies on the recurrence of urolithiasis: (1). Influence of diet on urinary excretion of the stone forming constituents].
    Murayama T, Taguchi H.
    Hinyokika Kiyo; 1987 Sep; 33(9):1321-30. PubMed ID: 3434487
    [Abstract] [Full Text] [Related]

  • 7. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers.
    Rattan V, Sidhu H, Vaidyanathan S, Thind SK, Nath R.
    Urol Res; 1994 Sep; 22(3):161-5. PubMed ID: 7992461
    [Abstract] [Full Text] [Related]

  • 8. [Clinical studies of the recurrence of urolithiasis (3). Influence of sodium intake on urinary excretion of calcium, uric acid, oxalate, phosphate and magnesium].
    Murayama T, Taguchi H.
    Hinyokika Kiyo; 1988 Sep; 34(9):1537-41. PubMed ID: 3213789
    [Abstract] [Full Text] [Related]

  • 9. Validity of biochemical findings in the evaluation of patients with urolithiasis.
    Tiselius HG, Larsson L.
    Eur Urol; 1980 Sep; 6(2):90-4. PubMed ID: 7358065
    [Abstract] [Full Text] [Related]

  • 10. Biochemical risk factors for stone formation in a Scottish paediatric hospital population.
    MacDougall L, Taheri S, Crofton P.
    Ann Clin Biochem; 2010 Mar; 47(Pt 2):125-30. PubMed ID: 20144971
    [Abstract] [Full Text] [Related]

  • 11. Comparison of urinary oxalate excretion in urolithiasis patients with and without hypercalciuria.
    Koide T, Bowyer RC, Brockis JG.
    Br J Urol; 1985 Oct; 57(5):505-9. PubMed ID: 4063729
    [Abstract] [Full Text] [Related]

  • 12. Urine composition following jejunoileal bypass.
    Nordenvall B, Backman L, Larsson L, Tiselius HG.
    Eur Urol; 1983 Oct; 9(1):35-9. PubMed ID: 6822241
    [Abstract] [Full Text] [Related]

  • 13. Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and magnesium oxide.
    Ahlstrand C, Tiselius HG.
    Br J Urol; 1984 Apr; 56(2):125-30. PubMed ID: 6498431
    [Abstract] [Full Text] [Related]

  • 14. Changes in urinary composition of calcium oxalate stone formers.
    Rahman B, Rahman MA.
    Biomed Pharmacother; 1986 Apr; 40(3):108-10. PubMed ID: 3742009
    [Abstract] [Full Text] [Related]

  • 15. Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease.
    Farmer RG, Mir-Madjlessi SH, Kiser WS.
    Cleve Clin Q; 1974 Apr; 41(3):109-17. PubMed ID: 4416806
    [No Abstract] [Full Text] [Related]

  • 16. Proceedings: Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease and relationship to urolithiasis.
    Farmer RG, Mir-Madjlessi SH, Kiser WS.
    Gut; 1973 Oct; 14(10):828. PubMed ID: 4758698
    [No Abstract] [Full Text] [Related]

  • 17. [Hydrochlorothiazide, allopurinol and magnesium oxide in the treatment of recurrent calcium urolithiasis].
    Musialik D, Głuszek J, Pieczyńska A.
    Pol Tyg Lek; 1973 Oct; 46(40-42):739-42. PubMed ID: 1669148
    [Abstract] [Full Text] [Related]

  • 18. Female stone disease: the changing trend.
    Marickar YM, Vijay A.
    Urol Res; 2009 Dec; 37(6):337-40. PubMed ID: 19779708
    [Abstract] [Full Text] [Related]

  • 19. The role of overweight and obesity in calcium oxalate stone formation.
    Siener R, Glatz S, Nicolay C, Hesse A.
    Obes Res; 2004 Jan; 12(1):106-13. PubMed ID: 14742848
    [Abstract] [Full Text] [Related]

  • 20. Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.
    Ahlstrand C, Tiselius HG.
    J Urol; 1981 Nov; 126(5):635-9. PubMed ID: 7299925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.